tiprankstipranks
Advertisement
Advertisement
Compass Pathways price target raised to $20 from $12 at Maxim
PremiumThe FlyCompass Pathways price target raised to $20 from $12 at Maxim
20d ago
Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings
Premium
The Fly
Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings
20d ago
Compass Pathways price target raised to $17 from $16 at Morgan Stanley
Premium
The Fly
Compass Pathways price target raised to $17 from $16 at Morgan Stanley
20d ago
Analyst Reiterates Buy on COMP360 Amid Accelerated Regulatory Momentum, Maintains $70 Price Target
PremiumRatingsAnalyst Reiterates Buy on COMP360 Amid Accelerated Regulatory Momentum, Maintains $70 Price Target
1M ago
Oppenheimer says CNPV designation strengthens case for Compass Pathways’ COMP360
Premium
The Fly
Oppenheimer says CNPV designation strengthens case for Compass Pathways’ COMP360
1M ago
Compass Pathways announces FDA granted NDA rolling review request
Premium
The Fly
Compass Pathways announces FDA granted NDA rolling review request
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100